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Understanding Patient Options, Utilization Patterns,
and Burdens Associated with Breast Cancer Screening
Susan C. Harvey, MD,1 Ashok Vegesna, PharmD,2 Sharon Mass, MD, FACOG,3
Janice Clarke, RN, BBA,2 and Alexandria Skoufalos, EdD2
Abstract
Despite ongoing awareness, educational campaigns, and advances in technology, breast cancer screening re-
mains a complex topic for women and for the health care system. Lack of consensus among organizations
developing screening guidelines has caused confusion for patients and providers. The psychosocial factors
related to breast cancer screening are not well understood. The prevailing algorithm for screening results in
significant rates of patient recall for further diagnostic imaging or procedures, the majority of which rule out
breast cancer rather than confirming it. For women, the consequences of the status quo range from unnecessary
stress to additional out-of-pocket expenses to indirect costs that are more difficult to quantify. A more
thoughtful approach to breast cancer screening, coupled with a research agenda that recognizes the indirect and
intangible costs that women bear, is needed to improve cost and quality outcomes in this area.
Introduction
Prevalence of breast cancer, relative risk of disease,
and associated morbidity and mortality
W ith the exception of skin cancers, breast cancercontinues to be the most commonly occurring cancer
among American women; approximately 1 in 8 U.S. women
(12%) is likely to develop invasive breast cancer by age 85.1
The American Cancer Society estimates that 232,340 new
cases of invasive breast cancer will be diagnosed and 40,000
women will die from the disease in 2014.
Breast cancer incidence is affected by numerous factors. In
the United States, rates of breast cancer vary by age, race/
ethnicity, and geographic location. Breast cancer is age de-
pendent; the chance that a woman will be diagnosed with the
disease at age 40 is 1:227 compared with 1:26 at age 70.2
White women have the highest incidence of breast cancer in
the U.S., followed closely by African American women.
Asian, Hispanic, and Native American women have a lower
risk of developing and dying from breast cancer.2,3
Genetic mutations can increase the risk of breast cancer;
however, the majority of breast cancers (85%) occur in
women without family history of the disease. In most cases,
the disease appears to be associated with spontaneous mu-
tations rather than heredity.1
Since 1990, breast cancer mortality has decreased signifi-
cantly. This decline is believed to be due to several factors
including improvements inmammography technology leading
to earlier detection, increased public awareness of the impor-
tance of screening, and improved treatment options. However,
breast cancer remains the second leading cause of cancer death
in women, exceeded only by lung cancer. The probability that
a woman’s death will be attributed to breast cancer is ap-
proximately 1 in 36 (approximately 3%). Clearly, breast can-
cer continues to be a significant public health concern.
Mammography is the only screening test for breast cancer
that has been shown to reduce mortality;2 specifically, it has
been associated with a 19% reduction in breast cancer deaths
(approximately 15% for women in their 40s and 32% for
women in their 60s).4 Overall, the sensitivity of mammog-
raphy (i.e., likelihood that the test will detect existing dis-
ease) is 70%–90%; however, for women with denser breast
tissue the sensitivity is lower (30%–48%).5
The benefit of mammography in terms of early detection of
cancer is balanced by certain limitations or ‘‘harms.’’4 One of
these unintended consequences is the need for additional
imaging or biopsy following the screening; in many cases, the
results of the further evaluation are benign, and often referred
to as ‘‘false positives.’’ The cumulative risk of a false positive
result for a 40- or 50-year-old woman undergoing annual
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mammography for 10 years is approximately 61%.4 For these
women, the need for additional testing can increase fear,
anxiety, and costs.
Current breast cancer screening guidelines
There are more clinical practice guidelines for breast
cancer screening than for almost any other medical proce-
dure. Contradictory recommendations from well-respected
professional organizations have caused confusion for cli-
nicians and patients alike (Table 1). Consider the case of a
hypothetical 45-year-old woman. The American College of
Obstetricians and Gynecologists (ACOG), the American
Cancer Society (ACS), and the National Comprehensive
Cancer Network (NCCN) recommend that she receive a
mammogram annually and that she should do self-exams
periodically as well.6 The National Cancer Institute (NCI)
recommends a mammogram every 1–2 years and advises
against self-exams. The U.S. Preventive Services Task
Force (USPSTF) advises against breast self-examination
and does not recommend a mammogram for her until age
50, at which time it advises biennial screening.7 Adding
further confusion, preventive service coverage mandated by
the Department of Health and Human Services through the
Affordable Care Act (ACA) follows earlier USPSTF 2002
recommendations for breast cancer screening, providing
coverage for mammographies beginning at age 40.
In a recent study, research analysts with the ACOG sur-
veyed 224 obstetrician-gynecologists to assess how the var-
ious guidelines influence their practices.8 Results indicated
that 83.5% of these clinicians were influenced by two or more
breast cancer screening guidelines. Although 42% reported
making at least one change after the release of the USPSTF
recommendations, 73% said that they were more influenced
by the ACOG and ACS guidelines. The existence of con-
flicting guidelines complicates the use of any single guideline
as the standard of practice in primary care and quality mea-
sures, as well as other settings.
Current screening technologies and approach
to diagnosis
Several types of technology are used for breast cancer
screening:9
 Film screen (analog) mammography. Now used in-
frequently in the United States, this previous standard
test uses x-rays to produce images of the breast on film.
 Digital mammography (full-field digital mammogra-
phy [FFDM]). These systems use solid-state detectors
to convert x-rays into electrical signals that produce
images of the breast that can be displayed on a com-
puter. From the patient’s perspective, a digital mam-
mogram and a film screen mammogram are similar;
however, the radiation dose for screening is lower with
digital imaging (approximately one-half of the dose
compared to film screen mammography).
 Computer-aided detection. These software programs
use a digitized film screen mammographic image or an
FFDM image to identify potential areas of distortion,
masses, or calcifications that may require further evalu-
ation by the radiologist to rule out the presence of cancer.
 Magnetic resonance imaging (MRI). Screening breast
MRI has been shown to increase the rate of cancer
detection. However, it may also show more findings for
follow-up that are not cancer, which can result in added
testing and unnecessary biopsies. Screening MRI is
typically only recommended for screening patients at
very high risk ( > 20% lifetime risk of breast cancer).
Some clinicians recommend MRI for women with in-
termediate risk (15%–20% lifetime risk of breast can-
cer) and dense breasts.
 Breast tomosynthesis (3-D mammography). A U.S.
Food and Drug Administration–approved new tech-
nology using a modification of the FFDM system, this
imaging method obtains multiple adjacent images that
are reconstructed into 1mm slices that can be reviewed
on a computer. The advantages include an increase in
Table 1. Conflicting Screening Guidelines
Organization
Initial breast
screening
Frequency
of screening
Clinical breast
examination schedule
Breast self-examination
instruction
American College of Obstetricians
and Gynecologists (ACOG)
40 years Annually Every 1–3 years from
ages 20–39 years
and annually at
ages 40 and older
Consider for high-risk
patients
American Cancer Society (ACS) 40 years Annually Every 1–3 years from
ages 20–39 years
and annually at
ages 40 and older
Optional for age 20 years
and older
National Comprehensive Cancer
Network (NCCN)
40 years Annually Every 1–3 years from
ages 20–39 years
and annually at
ages 40 and older
Recommended
National Cancer Institute (NCI) 40 years Every 1–2 years Recommended Not recommended
U.S. Preventive Services Task
Force (USPSTF)
Age 50–74
years
Every 2 years Insufficient evidence Not recommended
Adapted from American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin: Clinical Management Guidelines
for Obstetrician-Gynecologists. Obstet Gynecol 2011;118:372–382.
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detection of invasive cancer and a decrease in false
positive rates at screening.11
In the screening mammography setting with film screen
mammography or FFDM, approximately 10%–14% of women
are asked to return for further evaluation of a finding seen on the
mammogram, although it may vary by radiologist and by
site.12,13 On further evaluation with diagnostic mammography
and/or breast ultrasound, themajority of these findings are shown
to be the summation of normal tissue, cysts, or other benign
processes.11 A small percentage of women—about 2%—are
referred for breast biopsy. In some settings, more advanced im-
aging (e.g., MRI) is used for further assessment. The substantial
cost and potential stress of the added imaging evaluations are a
concern for health care providers, employers, public and com-
mercial payers, family members, and individual patients.
Cancer risk and breast density
The term ‘breast density’ describes the relative amount of
fatty and fibro-glandular breast tissue that is visible on a
mammogram. Mammographic breast density can impact
screening mammography in two ways. First, denser tissue
may make it more difficult to detect breast cancer (masking).
Second, dense breasts are an independent risk factor for
breast cancer. There are four categories of breast density:
 Almost entirely fatty, 10% of women;
 Scattered areas of fibro-glandular, 40% of women;
 Heterogeneously dense, 40% of women; and
 Extremely dense, 10% of women.
The 50% of women in the heterogeneously dense and
extremely dense categories are considered to have dense
breasts. Compared with women who have average breast
density, the risk of developing breast cancer for women with
heterogeneously dense breasts is 1.2 times greater than av-
erage, and the risk for women with extremely dense breasts is
2 times greater.14 A person’s risk depends upon breast density
plus other risk factors such as gene mutations, family history,
and personal history.15 Additional or alternate screening
options for women with dense breasts include MRI (de-
scribed above), ultrasound, and computerized tomography,
which differs from breast tomosynthesis. Whole breast ul-
trasound, the most commonly used modality, detects ap-
proximately 1 additional cancer for every 234 screenings.
However, ultrasound studies result in additional testing for
many women, including biopsy, with most of the biopsies
eventually found to be negative for cancer.16
In 2014, the ACOG Committee on Gynecologic Practice
issued an opinion to the effect that although women with
dense breasts have a ‘‘modestly increased risk of breast
cancer and experience reduced sensitivity of mammography
to detect breast cancer,’’ there is insufficient evidence to
advocate for additional testing.17 The Committee recom-
mended that health care providers comply with state laws
requiring them to disclose to patients their breast density as
indicated in a mammogram report.
Despite the ACOG Committee Opinion and a similar po-
sition statement from the American College of Radiology,18
many patients appear to be undergoing additional follow-up
Diagnostic imaging 
clinic calls woman 
to make 
appointment
Abnormal Results
Normal
Results
No further
 investigation 
required
Woman presents to 
primary health care 
provider regarding 
breast health
Diagnostic 
Mammogram
Tissue 
Diagnosis
Routine breast
MRI if lifetime
risk > 20%
Short Interval
Follow-Up
MRI
BI-RADS 1-2 BI-RADS 3 BI-RADS 4-5
Ultrasound
Woman participates 
in mammography 
screening
Reminder mailed
 when it’s time 
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BI-RADS: Breast Imaging Reporting and Data System
Likelihood of malignancy: BI-RADS 1-2: 0%; BI-RADS 3: > 0% and < 2%; BI-RADS 4: > 2% and < 95%; BI-RADS 5: > 95%
Short Interval: 6 months
FIG. 1. The typical mammography screening cycle (left side, in green), and the sequence of possible events following an
abnormal screening result (right side, in blue). Two-way arrows between types of diagnostic imaging represent the potential
for multiple imaging procedures occurring prior to Breast Imaging Reporting and Data System (BI-RADS) categorization
and subsequent management. Management after MRI (red arrows) may differ from other imaging modalities depending
upon BI-RADS categorization.
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testing, potentially increasing both cost and anxiety for these
patients. In contrast, the introduction of digital breast tomo-
synthesis has been shown to lower patient recall rates by up to
30%, with the greatest reduction in younger women and those
with denser breasts.19
Patient Perspectives on Breast Cancer Screening
From the patient perspective, breast cancer screenings, and
especially recalls, are often regarded as burdensome in terms
of anxiety, fear, confusion, and cost. The cycle of procedures
following an abnormal result can be particularly taxing on
women (Fig. 1). Misperceptions about screening processes,
lack of consensus opinion among professional organizations,
and additional costs associated with false positive results
(e.g., out-of-pocket, co-pay, deductible) all contribute to the
potential burden imposed on patients. Although some of
these factors are well documented, others are harder to elu-
cidate and can only be assumed based on the qualitative
research.
Fear of breast cancer screening
There has been a vast amount of research showing that
emotions, such as fear, can have a major impact on behav-
ior and that this reaction is central to patterns of patient
healthcare utilization or avoidance.20 Currently, it is unclear
whether fear is a barrier or facilitator of breast cancer
screenings.20 Also, it is important to recognize that some
behaviors and emotional responses to breast cancer screening
may vary by ethnicity and socioeconomic status. One study
found that compared with women of different backgrounds,
African American females displayed a generalized fear of the
health care system and a sense of fatalism (fear of imminent
death upon diagnosis of breast cancer).21 These factors may
contribute to the fact that African American women present
with breast cancer at later stages of the disease.3
Psychosocial impact of false positives
The psychosocial implications of having an inconclusive
screening mammogram vary significantly, and women ex-
perience a range of emotional responses.22,23 For example, in
a Swedish study with a small sample size, 13 women inter-
viewed after being recalled reported experiencing a ‘‘roller-
coaster’’ of emotions; some felt that the worst case scenario
was imminent, whereas others felt that being supported
by family members evoked feelings of strength and hope. For
almost all women, the uncertainty about a possible abnor-
mality resulted in an increase in anxiety.22 The stress expe-
rienced by women after an abnormal screening has been
shown to be transient in nature24 and is not likely to cause
long-term symptoms of depression or a deterioration of
overall mental health.25 However, one study has shown that
the emotional impact of additional views or biopsies can have
a powerful adverse short-term effect.26 Additionally, an in-
dividual patient who has multiple recalls from screening may
begin to question the accuracy and value of the examination.
Confusion due to mixed messaging
Variation in breast cancer screening guidelines is one
source of confusion for patients. As noted above, the ACOG,
ACS, NCCN, NCI, and USPSTF are not aligned in their
recommendations about when to initiate mammograms (age
40 or 50), the frequency of mammograms (annual vs. bien-
nial) or the advisability of breast self-exams. Media messages
also affect the public perception of the utility of cancer
screening.27 In a 2004 U.S. survey of 500 adults, 87% said
that they thought cancer screening was almost always a good
idea, with most indicating that they would overrule a physi-
cian who recommended against a screening.27 The extent to
which patients are aware of available options for breast
screening is also unclear. For instance, recent studies have
demonstrated that 3-D mammography can improve can-
cer detection11 as well as reduce recall rates from 15%–
63%.19,28–31 Targeted education would help raise awareness
of this option for patients seeking to gain earlier and more
accurate detection of breast cancer as well as to avoid being
recalled from screening. Further discussions could enable
women to make informed decisions regarding various
mammography options (e.g., preference for an insurance
carrier to provide coverage, or electing a test with a possible
out-of-pocket [OOP] cost but better accuracy in detecting
cancer and lower chance of recall for findings that are normal
on further evaluation).
Patient cost burden
There are a variety of ways that breast cancer screening—
and particularly false positive results—can be a financial
burden to a patient. In addition to the direct costs of imaging
studies (e.g., OOP costs, deductibles, co-pays), there are in-
direct costs such as missed time from work (or use of paid
time off), transportation, and caregiver costs (e.g., cost of
childcare or for elder care). Some studies have attempted to
quantify these costs;32,33 however, the results must be cau-
tiously interpreted. In a Norwegian study of breast cancer
screening costs, travel and lost productivity costs were pro-
jected using governmental estimates for travel reimburse-
ment and average pretax monthly salaries. These non-claims
based costs were shown to constitute 21% of the total OOP
costs to patients who were recalled, and 36% of the total OOP
cost to all patients who were screened.32 Although rough
estimates, these findings shed light on the impact OOP costs
may have on U.S. patients who are recalled due to false
positive screening results. Although these studies address
costs to women with health insurance, it is important to note
that women with low income and/or women who are unin-
sured bear a disproportionate cost burden.
When examining many patient-centric issues, government
and commercial payer claims data are insufficient; non-
claims cost data must be collected to properly measure the
extent to which indirect costs impact patients recalled due to
inconclusive mammograms.
Influence of Other Stakeholders
Payer-related issues
Public and private insurers play a major role in women’s
access to breast cancer screening and thus the stage at which
cancer is detected. Review of the current literature reveals a
wide gap in care between commercially insured women and
women who are publicly insured or uninsured.34 In a large
2007 U.S. study, researchers found that uninsured patients
and those covered by Medicaid were at considerably higher
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risk of being diagnosed with later stages of breast cancer
compared with women who had commercial insurance.34 In
addition to a low compliance with initial breast screenings,
another contributing factor to this disparity was that under-
insured patients were less likely to receive timely follow-up
of abnormal mammograms and were more likely to experi-
ence delays in treatment—both of which lead to increased
risk of cancer-related morbidity and mortality and can mag-
nify the cost burden for publicly funded programs.
Concerns about the cost of false positive recalls and in-
creased utilization costs impact all payers who provide cov-
erage for breast cancer screening. In a study of commercially
insured women, the mean avoidable cost to health plans per
recalled patient was reported as $1,238 compared with $0
for nonrecalled patients.35 The follow-up diagnostic services
that accounted for a majority of these costs included MRI,
guided (large core needle) biopsy and open (diagnostic ex-
cisional) biopsy, ultrasound, and additional mammography.
Biopsies alone accounted for two-thirds of recall expendi-
tures. The costs of additional procedures required for the
assessment of ultimately false positive results fall largely on
health care insurers. Furthermore, a retrospective review in
Connecticut using global Medicare reimbursement rates for
whole breast ultrasound, follow-up examinations, biopsy,
and aspiration found the additional costs of screening ultra-
sound for women with dense breasts was $180,802, or ap-
proximately $60,267 per cancer diagnosed.36 For employers
who self-insure, costs associated with false positive mammo-
graphy pose a particular concern.
Newer technologies are emerging with the potential to
improve quality and decrease costs associated with breast
cancer screening on both an individual and population basis.
As the evidence mounts regarding the ultimate value of these
modalities, commercial health plans and public payers should
give serious consideration to covering technologies that im-
prove quality and cost.
Health policy and the role of government
Government involvement in patient safety and quality as
they relate to mammography screening can be traced back to
1992, with the passage of the Mammography Quality Stan-
dards Act.37 Subsequent legislation has provided grants for
related research and funding for breast cancer screening
surveillance.
Similarly, since 1991, the Centers for Disease Control and
Prevention–funded National Breast and Cervical Cancer
Detection Program (NBCCDEP) has provided free or very
low-cost breast cancer screenings to women who are unin-
sured, who meet criteria for low income status, or who are
members of racial or ethnic minorities. Limited funding for
NBCCDEP enables the program to screen less than 1 in 8
eligible women aged 40 to 64 nationwide. Unfortunately,
funding is not likely to become available for the follow-up
imaging required for approximately 10% of screenings that
are interpreted as abnormal.
Since its passage in 2010, the ACA has made a substantial
impact on health care services and choices; in particular, it has
made health insurance available to more women andmandated
coverage for preventive services including screening mam-
mograms. The launch and continuing expansion of value-
based initiatives has enabled individual patients and provider
organizations alike to set priorities and make decisions based
on quality as well as cost. For example, health insurance ex-
changes and consumer-directed health plans enable individuals
to make value-based choices, and accountable care organiza-
tions and other risk-bearing health care provider entities as-
sume responsibility for both cost and quality health outcomes
of their patient populations. Future research is warranted to
assess the impact of the ACA on access to breast cancer
screening services and how this will translate into earlier de-
tection of breast cancer for new enrollees in health insurance
exchanges and Medicare and Medicaid beneficiaries.
To date, 18 states have passed ‘‘dense breast’’ legislation
requiring physicians to inform patients about their breast
tissue composition. The language and provisions of these
laws vary by state. Combined with conflicting guidance on
screening interval, these laws have caused a great deal of
confusion among women, their physicians, and radiologists
and, in some cases, have led to clinical recommendations that
are not congruent with position statements by the American
College of Radiology and the American College of Ob-
stetricians and Gynecologists, resulting in further confusion.
Individual Patient Risk and Needs Assessment
Multiple factors, such as age and breast density (as pre-
viously discussed), predispose women to varying risks for
breast cancer. This is critical to current and future discussions
pertaining to screening technology. Individual risk assess-
ment and tailored approaches to screening have the potential
to improve the value of the services that patients receive. It
has been shown that risk factors affect the sensitivity and
accuracy of mammography and ultimately impact the rate
of false positive tests and the overall cost burden on the health
care system.38 Although many have been reported, the most
significant risk factors associated with uncertain outcomes
and higher rates of recall are breast density and age. Breast
density is affected by a multitude of elements including
hormone replacement therapy, menstrual cycle phase, parity,
body mass index, and familial or genetic tendency.38 The
National Cancer Institute has developed a Breast Cancer Risk
Assessment tool designed to calculate a 5-year and lifetime
risk of breast cancer. The model uses a woman’s personal
medical history, reproductive history, and history of breast
cancer among her first-degree relatives to estimate her risk of
developing invasive breast cancer.39 In theory, this infor-
mation could be used by patients and their providers to in-
form decisions pertaining to screening options and advanced
diagnostic technologies.
A fundamental shift toward tailored screening and a
patient-centered approach must be accompanied by consen-
sus around consistent recommendations, updated protocols,
and revised algorithms designed to optimize value, elimi-
nate disparities, and create access to the most appropriate
technology.
Conclusions
Despite the vast amount of literature published about breast
cancer screening, significant gaps remain. In particular, little is
known about the indirect costs to patients resulting from re-
calls for further testing following an inconclusive mammo-
gram. Although useful for measuring direct costs, claims data
are limited in scope and cannot address a range of related
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issues that patients may face. The psychosocial impact of pa-
tient recalls is well documented; however, it is unclear how
this might translate into additional costs for women, healthcare
providers, employers, and payers.
The introduction of advanced breast screening technology
(e.g., digital breast tomosynthesis) may be helpful in ad-
dressing some of the issues discussed above. Improved in-
vasive cancer detection rates, and reduced false positive
interpretations, have the potential to positively impact indi-
vidual patients, the health care system as a whole, and health
care delivery organizations in terms of meeting or exceeding
quality benchmarks.
Optimizing the value of any new technology requires a
focused effort and targeted education for all stakeholders
(including patients) to ensure appropriate use and cost ef-
fectiveness. From a population health perspective, categor-
izing women by risk for breast cancer, and targeting effective
interventions to those specific risk populations is likely to
have a global positive effect. The concern is that our current
risk models are underdeveloped: they emphasize family
history when most breast cancers arise from spontaneous
mutations; they use breast density when the assessment is
subjective; and they use biopsy to prove a high-risk lesion
when not all are related to proliferative changes and subse-
quent risk. Ultimately, continued research and innovation
will enable us to better define risk and employ appropriate
screening technologies to reduce the frequency of patient
recalls and further improve breast cancer detection programs.
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